What is SepXiris® (AN69ST) ?
2018 Volume 15 Issue 3 Pages 238-241
Details
2018 Volume 15 Issue 3 Pages 238-241
SepXiris® is a membrane for continuous renal replacement therapy composed of AN69ST (surface-treated polyacrylonitrile). For its high cytokine adsorption ability, SepXiris®has been approved in Japan since 2014 to treat severe sepsis or septic shock patients. However, approval does not necessarily guarantee clinical effects. Therefore, we have reviewed published studies on the effect of SepXiris®, and evaluated the validity of its use in clinical practice. Our literature search found that most studies for SepXiris® on sepsis were animal experiments or in-vitro studies, and that clinical studies targeting sepsis were extremely limited. Additionally, there are many problems in the clinical studies that hamper showing any clinical benefit of SepXiris®. In conclusion, we have found that there is no evidence to support the use of SepXiris® for sepsis.
